We can’t show the full text here under this license. Use the link below to read it at the source.
Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in J apanese people with type 2 diabetes
Safety and effectiveness of weekly semaglutide compared to daily sitagliptin alone in Japanese people with type 2 diabetes
AI simplified
Abstract
Overall, 308 participants were randomized and exposed to treatment with semaglutide or sitagliptin.
- The discontinuation rate due to adverse events was higher in the semaglutide 1.0 mg group (14.7%) compared to both the semaglutide 0.5 mg and sitagliptin groups (2.9%).
- Treatment-emergent adverse events were reported more frequently in participants treated with semaglutide (74.8% for 0.5 mg and 71.6% for 1.0 mg) compared to sitagliptin (66.0%).
- Most adverse events associated with semaglutide were mild to moderate, with gastrointestinal issues being the most common.
- Mean glycated hemoglobin (HbA1c) decreased significantly with semaglutide (1.9% for 0.5 mg and 2.2% for 1.0 mg) compared to sitagliptin (0.7%).
- Body weight was reduced by 2.2 kg with semaglutide 0.5 mg and 3.9 kg with 1.0 mg, compared to no significant change with sitagliptin.
AI simplified
Key numbers
1.9%
Decrease in HbA1c
Change from baseline after 30 weeks of treatment
3.9 kg
Body weight reduction
Change from baseline after 30 weeks of treatment with semaglutide 1.0 mg
74.8%
Treatment-emergent adverse events
Proportion of participants reporting TEAEs with semaglutide 0.5 mg